SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma board to consider interim dividend

07 Aug 2015 Evaluate

With reference to the earlier letter dated July 31, 2015 informing that a Meeting of the Board of Directors of the Company will be held on August 12, 2015, to consider the Un-Audited Financial Results of the Company for the quarter ended June 30, 2015, Aurobindo Pharma has now informed that at the Board Meeting to be held on August 12, 2015, the Board will also consider the proposal of payment of Interim Dividend for the year 2015-16.

The above information is a part of company’s filings submitted to BSE.

Aurobindo Pharma Share Price

1371.80 -13.85 (-1.00%)
20-Apr-2026 12:56 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1670.35
Dr. Reddys Lab 1236.85
Cipla 1232.80
Zydus Lifesciences 942.40
Lupin 2332.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×